Clinical Trial

Role of ROS and cAMP-PKA Biomarkers in ADPKD

Name: Role of ROS and cAMP-PKA Biomarkers in ADPKD — clinical trial record (NCT07217158)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-10-13.

Trial Details

NCT Number	NCT07217158
Lead Sponsor	Mayo Clinic Collaborators: United States Department of Defense
Conditions	Autosomal Dominant Polycystic Kidney Disease
Enrollment	100 participants
Start Date	2023-07-01
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-10-27